Related Experiment Video

Updated: May 13, 2026

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

FES eQTL suppresses the progression of primary aldosteronism by regulating CD3 on TD CD8br immune cells: Mendelian

Cai Deng1, Huasheng Liao2, Yizhao Wu1

  • 1The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China.

Mammalian Genome : Official Journal of the International Mammalian Genome Society
|May 11, 2026
PubMed

Insights

Researchers identified a new genetic target, FES eQTL, that may reduce primary aldosteronism (PA) risk by influencing immune cells. This finding offers potential new therapeutic strategies for PA diagnosis and treatment.

Area of Science:

  • Endocrinology and Metabolism
  • Genetics
  • Immunology

Background:

  • Primary aldosteronism (PA) pathogenesis is not fully understood.
  • Current treatments for PA have limitations, necessitating new therapeutic targets.
  • Identifying novel diagnostic and therapeutic strategies for PA is crucial.

Purpose of the Study:

  • To identify novel therapeutic targets for the diagnosis and treatment of primary aldosteronism (PA).
  • To investigate the relationship between FES eQTL expression and PA risk.
  • To elucidate the metabolic mechanisms underlying the influence of FES eQTL on PA.

Main Methods:

  • Two-sample Mendelian randomization (MR) analysis
  • Colocalization analysis
  • Summary data-based Mendelian randomization (SMR) analysis
  • Mediation analysis

Main Results:

  • Increased FES eQTL expression was significantly associated with reduced PA risk.
  • FES eQTL influences PA risk through immune cell modulation, specifically affecting CD3 expression on TD CD8br immune cells.
  • Elevated CD3 expression on TD CD8br immune cells was linked to decreased PA risk.

Conclusions:

  • FES eQTL is a novel cis-eQTL-mediated susceptibility gene that can reduce PA risk.
  • FES suppresses PA through a metabolic mechanism involving the regulation of CD3 on TD CD8br immune cells.
  • The FES eQTL presents a potential new therapeutic target for PA diagnosis and treatment.
Keywords:
Immune cellsMediation analysisMendelian randomizationPAcis-eQTL

More Related Videos

A Novel Method: Super-selective Adrenal Venous Sampling06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.